ERBB2 and cancer: For example, only 15%–30% of Her2-positive patients respond to trastuzumab therapy due to de novo and acquired resistance.10, 11 Trastuzumab has minimal effects on Her2 low- or medium-expression cancer cells in vivo and in vitro.